WebAug 1, 1997 · Because cardiotoxicity was not observed withthis combination, we added cyclophosphamide (Cytoxan, Neosar) in a phaseII trial to determine the antitumor activity and tolerability of this 3-drugcombination as first-line therapy in patients with metastatic breast cancer.Preliminary results from this study indicate that the Taxotere/Adriamycin ... http://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Breast/BRAJTDC_Protocol.pdf
Efficacy of neo-adjuvant chemotherapy with TEC regimen on
WebDec 6, 2024 · INTRODUCTION. The taxanes, paclitaxel (Taxol), nanoparticle albumin-bound paclitaxel (nabpaclitaxel [Abraxane]), docetaxel (Taxotere), and cabazitaxel (Jevtana), are anti-microtubulin drugs that have a broad range of antitumor activity. These agents have the potential to induce pulmonary injury through a variety of mechanisms: WebBackground: Docetaxel plus cyclophosphamide (TC) has recently been established as a standard adjuvant chemotherapy regimen for HER2-negative (HER2-) operable breast … cervical length and funneling
Docetaxel/doxorubicin/cyclophosphamide in the treatment of
WebBackground: Previous results suggest that docetaxel plus cyclophosphamide improves disease-free survival (DFS) and overall survival compared with doxorubicin plus cyclophosphamide in early stage breast cancer. We assessed the addition of 1 year of trastuzumab to a non-anthracycline regimen, docetaxel plus cyclophosphamide, in … WebPreliminary results from this study indicate that the Taxotere/ Adriamycin/Cyclophosphamide (TAC) combination produces response rates of up to 80%. However, frequent grade 4 neutropenia was seen in 68% of cycles, febrile neutropenia in 5.5% of cycles, and grade 3 to 4 infection in .8% of cycles. Webafter chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC (1.1) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC (1.2) cervical landmarks